Synta Pharmaceuticals Corporation

Other

Shionogi Bioresearch Corporation

Quercegen Pharma LLC

Sola Biosciences, LLC

Shiongi Bioresearch Corp.

Keizo Koya

Lijun Sun

Shoujun Chen

Mitsunori Ono

Noriaki Tatsuta

Weiwen Ying

Zhi-Qiang Xia

Yaming Wu

Hao Li

Jun Jiang

Takayo Inoue

Elena Kostik

Shijie Zhang

Zhenjian Du

Christopher Borella

Guiqing Liang

Kevin Paul Foley

David James

Zachary Demko

Dinesh U Chimmanamada

Farid Vaghefi

Teresa Przewloka

Yumiko Wada

Lan Bo Chen

Naoto Yamaguchi

Teresa Kowalczyk-Przewloka

Mei Zhang

Dan Zhou

Sylvia Holden

Wojciech Wrona

Howard P Ng

Natalie Alysia Dales

Junghyun Chae

Shuzhen Qin

Minghu Song

Chi-Wan Lee

Xueliang Tao

Luca Rastelli

Patricia Rao

Masazumi Nagai

Ronald K Blackman

Yuniko Wada

Akinori Hishiya

Teresa Kowalcyzk-Przewloka

Timothy Korbut

Teresa Kowalczyk Przewloka

Fusion proteins comprising a protein expression enhancing polypeptide linked to a target protein binding domain and nucleic acid molecules encoding such fusion proteins are described for use in enhancing expression and/or location of a targeted protein of interest, for restoring lost functions in cells, and for treating disease. Additional fusion proteins comprising a target protein of interest modified with a fusion partner comprising a protein expression enhancing polypeptide are also disclosed.

Protein expression enhancing polypeptides

Disclosed are compounds of formulae (I), (III), (IV), (VII), (X), (XI), (XII), (XIII) and (XIV), wherein the variables are as defined in the claims, and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.

Compounds for treating proliferative disorders

The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

Triazole compounds that modualte HSP90 activity

Disclosed is a compound represented by the Structural Formula (I):  Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with Paclitaxel or an analog of Paclitaxel.

Paclitaxel enhancer compounds

Disclosed are compounds and pharmaceutical compositions that are useful for treating a subject with a proliferative disorder, such as cancer. The disclosed compounds and pharmaceutical compositions are also useful for treating disorders responsive to Hsp70 induction and/or natural killer induction.

Compounds for the treatment of proliferative disorders

The invention relates to compounds of structural formula (I): 

Triazole compounds that modulate HSP90 activity

Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.

Improved cancer treatments with bis[thiohydrazide amide] compounds such as elesclomol, in particular for identifying patient populations that would benefit from such treatments.

[object Object]

Disclosed are compounds of formula (IA), formula (IV) or formula (V), wherein the variables are as defined herein, and pharmaceutical compositions containing them which are useful for treating a subject with a proliferative disorder, such as cancer. The disclosed compounds and pharmaceutical compositions are also useful for treating disorders responsive to Hsp70 induction and/or natural killer induction. 

Disclosed herein are methods of preparing a bis(thio-hydrazide amides) compounds of the following structural formula: wherein R, R, R, R, R, Rand Rare defined herein. 

Process for preparing bis(thiohydrazide amides)

Disclosed herein are oral formulations of bis(thio-hydrazide amides) compounds of the following structural formula (I): or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, Z, and Y are defined herein. 

Oral formulations of bis(thiohydrazide amides)

Growing community of inventors

Chestnut Hill, MA, United States of America

Keizo Koya